Legal Basis of US Medical Device Registration under the FD&C Act

1. Key takeaways

The parent statute for United States medical device registration obligations is the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 510 [21 U.S.C. 360] establishes establishment registration and device listing, section 502(o) [21 U.S.C. 352(o)] provides that a device not listed as required is misbranded, and section 801 [21 U.S.C. 381] authorizes FDA, together with Customs, to regulate imported products. Together these three provisions form a single legal chain: without registration there can be no listing, and without compliance there can be no import. Every practical step a foreign manufacturer takes toward the United States market ultimately traces back to one of these statutory anchors, which is why a working knowledge of the statute itself, rather than only of the implementing regulations, is worth building into any compliance program from the outset.

• Registration under section 510(i)(1) attaches when a foreign establishment begins manufacturing, preparation, propagation, compounding, or processing, with annual renewal each October 1 through December 31.
• Listing duties under section 510(j) carry the same annual renewal window.
• Section 502(o) classifies an unlisted device as misbranded, which is the legal predicate for detention at import.
• Section 801 governs import oversight and underpins the dual Customs and FDA entry process.
• FDASIA, signed on 2012-07-09, wrote the foreign variable into the statute: products of unregistered foreign establishments are misbranded.

2. Legal basis

The authorities below are the provisions most frequently invoked in the registration, listing, and import chain, including the exact citations quoted by Import Alert 99-34 when FDA detains shipments from establishments that have failed to register or list. Readers should treat the statute and its citations as the controlling text; the commentary in this guide explains how those texts connect, but never replaces them.

3. Expert insights

Insight one: the trigger for registration is the commencement of the activity, not the moment a product reaches the market.

Under FD&C Act section 510(i)(1), a foreign establishment must register at the time it begins manufacturing, preparation, propagation, compounding, or processing, and must complete annual registration renewal between October 1 and December 31 of each following year. This means that shipping first and registering afterwards has no legal footing. The statute ties the obligation to the conduct of the activity itself, so the question a compliance team should ask is not whether any product has been sold yet, but whether any regulated activity has begun at the site. Once the answer is yes, the clock has already started, and every shipment dispatched in the interim carries the defects described below.

Insight two: the legal characterization of failure to list is misbranding, and the consequence is detention rather than a fine that can be paid and forgotten.

Section 502(o) characterizes an unlisted device directly as a misbranded article. At the border, this translates into detention without physical examination (DWPE) under Import Alert 99-34: the goods cannot be released until FDA takes a position, and they may be detained without an unpacking inspection. The practical significance is that misbranding is not a paper defect that can be cured by paying a penalty; it is a status that blocks the consignment at the port of entry. Shippers discover this at the worst possible moment, with goods already en route, which is why the registration, listing, and customs declarations must be treated as one continuous chain rather than three independent chores.

Insight three: FDASIA wrote the foreign variable into the statutory text itself.

FDASIA, signed on 2012-07-09, amended the FD&C Act to make explicit that drugs and medical devices produced in unregistered foreign establishments are misbranded. This is not an internal FDA interpretation or an enforcement preference; it is an express statement at the level of the statute, and it is the direct legal support for Import Alert 99-34. For foreign manufacturers, the takeaway is that the United States obligations are not anchored in administrative guidance that might shift with policy, but in binding legislation. Compliance planning should therefore start from the statute and the regulations, and any advice that suggests the foreign origin of a product softens the legal duties should be discarded immediately.

4. Practical recommendations

• Treat registration, listing, and customs declaration as one chain: if any one of the three is missing, the consignment can be detained at the border, so no shipment should be booked until all three links are confirmed in place.
• Complete initial registration of the foreign manufacturing establishment before signing the first United States purchase order, and do not wait for the first shipment to trigger the work.
• Under OEM or contract manufacturing arrangements, verify the registration and listing status of each contract manufacturer individually; the brand owner’s own registration does not cover the contract facility.
• Maintain an annual calendar: complete the annual renewal of registration and listing between October 1 and December 31 each year, since missing the window moves the establishment into a failed to register or failed to list status.

5. Verification checklist

• □ The registration trigger timing under FD&C Act section 510(i)(1) has been confirmed against the company’s own situation.
• □ The consequences under section 502(o) have been confirmed and written into the internal shipment release conditions.
• □ A calendar reminder for the October 1 to December 31 annual renewal has been established.
• □ The registration and listing status of all contract manufacturers has been verified.
• □ Documentation for the dual Customs and FDA declaration under section 801 has been prepared.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com